Health Technology Acrs

Aclaris Therapeutics, Inc.

ACRS | $1.225 0.41% 310K

(0.0% 1d) (5.2% 1m) (-86.6% 1y) (0.0% 2d) (0.0% 3d) (-0.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 86,883,176
http://www.aclaristx.com
Sec Filling | Patents | 77 employees

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

immunology rheumatoid arthritis aesthetic msa

Drugs

Rhofade (oxymetazoline Hydrochloride)

add to watch list Paper trade email alert is off

Press-releases

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
ACRS | $1.225 0.41% 310K

Health Technology

| 0.0% | O: 2.05% H: 0.0% C: 0.0%
therapeutics

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
LLY | News | $741.37 1.37% 800K

Health Technology

| -5.26% | O: -2.2% H: 2.39% C: 1.34%
ACRS | $1.225 0.41% 310K

Health Technology

| 0.83% | O: 2.48% H: 10.48% C: -3.23%
year update therapeutics financial results

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| 32.03% | O: 14.72% H: 17.92% C: 9.43%
business review therapeutics

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| -4.69% | O: -16.41% H: 6.54% C: -6.07%
ati-1777 dermatitis trial therapeutics results

Aclaris Therapeutics Provides Corporate Update
Published: 2023-12-19 (Crawled : 21:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| 19.61% | O: -2.78% H: 0.84% C: -5.71%
update therapeutics

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Published: 2023-12-05 (Crawled : 21:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| 23.68% | O: 9.49% H: 6.48% C: -5.56%
pharma patent license therapeutics agreement

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| -74.34% | O: -85.28% H: 0.0% C: -7.87%
ati-450 update trial therapeutics results

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $741.37 1.37% 800K

Health Technology

| 25.53% | O: -1.66% H: 0.0% C: 0.0%
ACRS | $1.225 0.41% 310K

Health Technology

| -77.28% | O: 1.12% H: 5.06% C: 0.92%
update therapeutics financial results

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| -81.89% | O: 0.97% H: 2.65% C: -7.94%
ati-1777 dermatitis therapeutics study

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Published: 2023-09-20 (Crawled : 11:00) - globenewswire.com
ACRS | $1.225 0.41% 310K

Health Technology

| -83.56% | O: -0.27% H: 0.88% C: -8.51%
conference global therapeutics

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-24-004385	4	2024-03-05	2024-03-04	Buy	P	6000	28863
0001209191-24-004385	4	2024-03-05	2024-03-01	Buy	P	8500	22863